TNFSF13B and lobular neoplasia: Indeed, recent trial successes resulted in approval by regulatory agencies of the two first in history drugs for LN, i.e., the new generation calcineurin inhibitor voclosporin (Rovin et al. 2019, 2021) and the monoclonal antibody against B cell activating factor (BAFF; also known as B lymphocyte stimulator, BLyS) belimumab (Furie et al. 2020), as add-on treatments on top of standard disease modifying therapy (Fanouriakis et al. 2020).